Richard Nolan Townsend - 04 Feb 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Youjin Choi, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
4
Filing time
06 Feb 2026, 17:00:12 UTC
Previous filing
20 Nov 2025
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Townsend Richard Nolan Chief Executive Officer, Director C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK /s/ Youjin Choi, Attorney-in-Fact 06 Feb 2026 0001995218

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Award $0 +161,665 +67% $0.000000 402,656 04 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Stock Option (right to buy) Award $0 +646,665 $0.000000 646,665 04 Feb 2026 Common Stock 260,000 $7.27 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2027, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Includes 290,022 RSUs.
F3 25% of the shares underlying the option vest and become exercisable on February 4, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.